Contrary to other genetically defined AML, AML with BCR::ABL1 still requires ≥20% blasts for diagnosis to avoid potential overlap with accelerated phase of chronic myeloid leukemia (CML-AP). This evidence concerns the gene BCR and acute myeloid leukemia.